vatalanib has been researched along with azomycin in 1 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (azomycin) | Trials (azomycin) | Recent Studies (post-2010) (azomycin) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 4,790 | 418 | 1,580 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bali, S; Bhutta, MF; Brown, SD; Cheeseman, MT; Hilton, H; Hough, TA; Parker, A; Pathak, P; Potter, PK; Purnell, T; Romero, MR; Tyrer, HE; Vizor, L; Vowell, K; Wells, S; Williams, D | 1 |
1 other study(ies) available for vatalanib and azomycin
| Article | Year |
|---|---|
HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.
Topics: Animals; Blister; Body Fluids; Cell Hypoxia; Disease Models, Animal; Ear, Middle; Gene Expression Regulation; Hearing Loss; HSP90 Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Mutant Strains; Nitroimidazoles; Otitis Media with Effusion; Phthalazines; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |